Repligen Acquires TangenX for $39M

0


Repligen said today it has acquired TangenX Technology from Novasep Holding for $39 million in a deal that adds to the bioprocessing company’s single-use technology offerings and broadens its offerings to include downstream manufacturing processes.

TangenX makes the single-use Sius™ line of tangential flow filtration (TFF) cassettes and hardware, an offering Repligen said complements its OPUS® line of prepacked chromatography columns used in downstream purification.

The companies say the Sius TFF cassettes are designed to deliver superior performance to traditional reusable TFF cassettes in a convenient and flexible format that is also economical. Sius TFF cassettes are interchangeable with filter hardware from multiple manufacturers, simplifying customer trial and adoption of Sius products.

Use of Sius TFF in downstream processing has typically reduced filter costs by 80%, labor by 50%, and buffer usage by 75%, eliminating cleaning and flushing steps, according to TangenX studies.

Repligen said the Sius portfolio will also strengthen its existing capability in filtration, where its XCell™ ATF products (both stainless steel and single-use) are used for perfusion and cell culture intensification in upstream manufacturing processes.

“This strategic acquisition strengthens our position as a leader in single-use bioprocessing technologies and extends our reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers for the convenience, flexibility, and cost advantages that they offer,” Repligen President and CEO Tony J. Hunt said in a statement.

Repligen acquired TangenX in a €37 million ($39 million) all-cash transaction.

In the coming year, the buyer said, sales of TangenX products are expected to grow by double digits and contribute $7 million to $7.5 million in revenue. Repligen also expects the acquisition to add to its GAAP earnings per share (EPS) and adjusted EPS in 2017.

TangenX has been a subsidiary of Novasep since it took a majority stake in the Shrewsbury, MA, company in 2006. Novasep Chairman and CEO Michel Spagnol, Ph.D., said in a company statement that the deal reflected a 3-year strategy of refocusing on core activities for his company, a global provider of manufacturing solutions designed to be cost-effective and sustainable for life sciences molecules and fine chemicals.

“Repligen's infrastructure, which is perfectly adapted to the Sius range, will help to develop the product at the pace this technology deserves,” Dr. Spagnol said.








This site uses Akismet to reduce spam. Learn how your comment data is processed.